Please wait

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Name of Issuer)

(Title of Class of Securities)

(CUSIP Number)

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

X0202 SCHEDULE 13D/A 0001982476 XXXXXXXX LIVE 1 Common Stock, par value $0.0001 per share 06/02/2026 false 0001704287 095633608 Bluejay Diagnostics, Inc. 360 Massachusetts Avenue Suite 203 Acton MA 01720 Ross. D. Carmel, Esq. (212) 930-9700 1185 Avenue of the Americas 26th Floor New York NY 10036 0001982476 N Braeden Lichti PF N Z4 0.00 0.00 0.00 0.00 0.00 N 0.00 IN On June 2, 2026, Mr. Lichti sold all of his previously owned shares of the Issuer's common stock and no longer beneficially owns any shares of common stock of the Issuer. Accordingly, this filing is the final amendment to the Schedule 13D and constitutes an exit filing for the Reporting Person. Y Northstrive Fund II LP WC N DE 0.00 0.00 0.00 0.00 0.00 N 0.00 PN Braeden Lichti is, as of the date of this Schedule 13D, the Manager of Northstrive Fund II LP ("Northstrive Fund"). On June 2, 2026, Northstrive Fund sold all of its previously owned shares of the Issuer's common stock and no longer beneficially owns any shares of common stock of the Issuer. Accordingly, this filing is the final amendment to the Schedule 13D and constitutes an exit filing for the Reporting Persons. Common Stock, par value $0.0001 per share Bluejay Diagnostics, Inc. 360 Massachusetts Avenue Suite 203 Acton MA 01720 Mr. Braeden Lichti and Northstrive Fund previously filed a Schedule 13D on March 11, 2026. This Amendment No. 1 relates to the Common Stock of the Issuer and amends the Schedule 13G. The principal executive offices of the Issuer are located at 360 Massachusetts Avenue, Suite 203, Acton, MA 01720. Mr. Lichti serves as the Manager of Northstrive Fund. As of the date of this Amendment, neither Reporting Person beneficially owns any shares of the Issuer's Common Stock, as reflected on the cover pages and in Item 5. The address of each of the Reporting Persons is 120 Newport Center Drive, Newport Beach, CA 92660. Northstrive Fund is principally engaged in the business of investments into private and public securities. Mr. Lichti is principally engaged as the Chief Executive Officer of Northstrive Companies Inc., a California based management, advisory and investment company. Mr. Lichti has not, during the last five years, been convicted in a criminal proceeding (excluding traffic violations and similar misdemeanors). None of the Reporting Persons have, during the last five years, been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree, or final order enjoining future violations of, or prohibiting or mandating activities subject to, Federal or state securities laws or finding any violation with respect to such laws. Northstrive Fund is a Delaware limited partnership. Mr. Lichti is a citizen of Canada. Not applicable. This Amendment reports only the disposition of all shares previously reported on the Schedule 13D and no additional securities were acquired since the Schedule 13D filed with the SEC on March 11, 2026 As of the date of this Amendment, the Reporting Persons beneficially own 0 shares of the Issuer's Common Stock. Since the filing of the Reporting Persons' Schedule 13D with the SEC on March 11, 2026, the Reporting Persons have disposed of all shares of common stock of the Issuer. As of June 2, 2026, the Reporting Persons no longer beneficially own any shares of the Issuer's Common Stock. As of the date of this Amendment, the Reporting Person do not beneficially own any shares of the Issuer's common stock. The information set forth on the cover pages of this Amendment is incorporated herein by reference. Sole power to vote or to direct the vote: Braeden Lichti: 0 shares Northstrive Fund II LP: 0 shares Shared power to vote or to direct the vote: Braeden Lichti: 0 shares Northstrive Fund II LP: 0 shares Sole power to dispose or to direct the disposition of: Braeden Lichti: 0 shares Northstrive Fund II LP: 0 shares Shared power to dispose or to direct the disposition: Braeden Lichti: 0 shares Northstrive Fund II LP: 0 shares The information set forth in Item 3 above is incorporated herein by reference. Not applicable. As of June 2, 2026, the Reporting Persons ceased to be beneficial owners of more than five percent of the Issuer's outstanding Common Stock. This Amendment is the final amendment to the Schedule 13D and constitutes an exit filing for the Reporting Persons. The information in Items 3 and 4 is incorporated herein by reference. Braeden Lichti /s/ Braeden Lichti Braeden Lichti 06/02/2026 Northstrive Fund II LP /s/ Braeden Lichti Braeden Lichti/Manager 06/02/2026